Hirokazu Tanaka

TL;DR: Large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.

TL;DR: Results indicate that the prognosis of AML could be stratified by the major mutation status in combination with cytogenetics, and that AML patients could be clearly stratified into five risk groups for overall survival by including the mutation status of DNMT3A, MLL-PTD and TP53 genes in the risk classification system of the European LeukemiaNet.

TL;DR: The exploration of clinical and functional consequences suggests that PRPF8 is a novel leukemogenic gene in myeloid neoplasms with a distinct phenotype likely manifested through aberrant splicing.

TL;DR: Comparing gene expression profiles for HSCs and early lymphoid progenitors revealed that Satb1, a global chromatin regulator, was markedly induced with lymphoid lineage specification, and governs the initiating process central to the replenishing of lymphoid lineages.

TL;DR: Cross-sectionally, the frequencies of these mutations increased from lower- to higher risk disease, thus suggesting a role in clinical progression and Variant allelic frequencies indicated that IDH1MT and IDH2MT are ancestral in up to 14/74 (19%) vs 34/99 (34%; P=0.027) of cases, illustrating the pathogenic role of these lesions in myeloid neoplasms.